Dosage Form: First-line maintenance treatment of advanced ovarian cancer: For patients weighing <77 kg (<170 lbs) OR with a platelet count < 150,000/μL, the recommended dose is 200 mg taken orally once daily. (2.2) For patients weighing ≥77 kg (≥170 lbs) AND a platelet count ≥150,000/μL, the recommended dose is 300 mg taken orally once daily. (2.2) For other indications: The recommended dose is 300 mg taken orally. (2.2) ZEJULA can be taken with or without food.
Side Effect:Most common adverse reactions (incidence ≥10%) of patients who received ZEJULA were nausea, thrombocytopenia, anemia, fatigue, constipation, musculoskeletal pain, abdominal pain, vomiting, neutropenia, decreased appetite, leukopenia, insomnia, headache, dyspnea, rash, diarrhea, hypertension, cough, dizziness, acute kidney injury, urinary tract infection, and hypomagnesemia.